A US medical device company wanted to understand how UK payers would view their technology. They engaged Alacrita to find out.
We carried out desk research to develop the technology’s value proposition. We then convened a payer advisory board, comprising a member of the National Institute for Health and Care Excellence (NICE), a director of NHS commissioning as well as payers from regional NHS trusts to understand on what basis payers would evaluate the technology, what comparators would be used and to assess payers’ reactions to the proposed data package based on the currently designed clinical trial and supporting information. We presented a better understanding of the evidence payers require to approve a new medical intervention and provided clear recommendations as to how the company should collect that data.Back